Irritable bowel syndrome: a concise review of current treatment concepts

doi:10.3748/wjg.v20.i27.8796

Review

. 2014 Jul 21;20(27):8796-806.

doi: 10.3748/wjg.v20.i27.8796.

Irritable bowel syndrome: a concise review of current treatment concepts

Geoffrey C Wall¹, Ginelle A Bryant¹, Michelle M Bottenberg¹, Erik D Maki¹, Andrew R Miesner¹

Affiliations

Affiliation

¹ Geoffrey C Wall, Ginelle A Bryant, Michelle M Bottenberg, Erik D Maki, Andrew R Miesner, Department of Pharmacy Practice, Drake University College of Pharmacy, Des Moines, IA 50311, United States.

PMID: 25083054
PMCID: PMC4112883
DOI: 10.3748/wjg.v20.i27.8796

Review

Irritable bowel syndrome: a concise review of current treatment concepts

Geoffrey C Wall et al. World J Gastroenterol. 2014.

. 2014 Jul 21;20(27):8796-806.

doi: 10.3748/wjg.v20.i27.8796.

Authors

Geoffrey C Wall¹, Ginelle A Bryant¹, Michelle M Bottenberg¹, Erik D Maki¹, Andrew R Miesner¹

Affiliation

¹ Geoffrey C Wall, Ginelle A Bryant, Michelle M Bottenberg, Erik D Maki, Andrew R Miesner, Department of Pharmacy Practice, Drake University College of Pharmacy, Des Moines, IA 50311, United States.

PMID: 25083054
PMCID: PMC4112883
DOI: 10.3748/wjg.v20.i27.8796

Abstract

Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders causing patients to seek medical treatment. It is relatively resource intensive and the source of significant morbidity. Recent insights into the pathophysiology and treatment of IBS has given clinicians more options than ever to contend with this disorder. The purpose of our paper is to review older, "classic" treatments for IBS as well as newer agents and "alternative" therapies. We discuss the evidence base of these drugs and provide context to help develop appropriate treatment plans for IBS patients.

Keywords: Irritable bowel syndrome; Linaclotide; Lubiprostone; Peppermint oil; Probiotics; Rifaximin.

PubMed Disclaimer

Figures

**Figure 1**
Treatment algorithm for irritable bowel syndrome. IBS: Irritable bowel syndrome; TCA: Tricyclic antidepressant; SSRI: Selective serotonin reuptake inhibitor; D/C: Discontinue.

See this image and copyright information in PMC

Cited by

Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
Zeber-Lubecka N, Kulecka M, Ambrozkiewicz F, Paziewska A, Goryca K, Karczmarski J, Rubel T, Wojtowicz W, Mlynarz P, Marczak L, Tomecki R, Mikula M, Ostrowski J. Zeber-Lubecka N, et al. Gut Microbes. 2016 Sep 2;7(5):397-413. doi: 10.1080/19490976.2016.1215805. Epub 2016 Jul 26. Gut Microbes. 2016. PMID: 27662586 Free PMC article.
Pre-Antibiotic Treatment Followed by Prolonged Repeated Faecal Microbiota Transplantation Improves Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome: An Observational Australian Clinical Experience.
Hamblin H, Gunaratne AW, Clancy A, Pilarinos D, LeBusque A, Dawson MVM, Borody TJ. Hamblin H, et al. Gastroenterol Res Pract. 2022 Oct 13;2022:6083896. doi: 10.1155/2022/6083896. eCollection 2022. Gastroenterol Res Pract. 2022. PMID: 36275423 Free PMC article.
Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome: A Bridge between Functional Organic Dichotomy.
Ghoshal UC, Shukla R, Ghoshal U. Ghoshal UC, et al. Gut Liver. 2017 Mar 15;11(2):196-208. doi: 10.5009/gnl16126. Gut Liver. 2017. PMID: 28274108 Free PMC article. Review.
Lipi Guben decoction in treating diarrheal irritable bowel syndrome: A study protocol for a randomized controlled trial.
Yang H, Liu X, Peng W, Chen R, Chen Y. Yang H, et al. Medicine (Baltimore). 2021 Jan 22;100(3):e23887. doi: 10.1097/MD.0000000000023887. Medicine (Baltimore). 2021. PMID: 33545956 Free PMC article.
Effect of probiotics and dietary fiber combined with pinaverium bromide on intestinal flora in patients with irritable bowel syndrome.
Sun H, Li X, Chen W, Jia F, Su J, Zhang B, Wu X, Wu P. Sun H, et al. Am J Transl Res. 2021 Dec 15;13(12):14039-14045. eCollection 2021. Am J Transl Res. 2021. PMID: 35035746 Free PMC article.

See all "Cited by" articles

References

1. Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011;123:122–132. - PubMed
1. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47:1177–1185. - PubMed
1. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176. - PMC - PubMed
1. Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006;24:183–205. - PubMed
1. Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol. 2008;8:724–728. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011;123:122–132. - PubMed

[2] Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011;123:122–132. - PubMed

[3] Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47:1177–1185. - PubMed

[4] Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol. 2012;47:1177–1185. - PubMed

[5] Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176. - PMC - PubMed

[6] Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159–176. - PMC - PubMed

[7] Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006;24:183–205. - PubMed

[8] Tack J, Fried M, Houghton LA, Spicak J, Fisher G. Systematic review: the efficacy of treatments for irritable bowel syndrome--a European perspective. Aliment Pharmacol Ther. 2006;24:183–205. - PubMed

[9] Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol. 2008;8:724–728. - PubMed

[10] Pohl D, Tutuian R, Fried M. Pharmacologic treatment of constipation: what is new? Curr Opin Pharmacol. 2008;8:724–728. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Irritable bowel syndrome: a concise review of current treatment concepts

Affiliation

Irritable bowel syndrome: a concise review of current treatment concepts

Authors

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Abstract

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources